Estrella Immunopharma (ESLA) Current Assets (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Current Assets of $2.2 million for Q1 2026, up 128.45% year-over-year from $944268.0 in Q1 2025, and up 28.64% quarter-over-quarter from $1.7 million in Q4 2025.
Estrella Immunopharma (ESLA) Current Assets (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Current Assets for 6 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 128.45% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 128.45% YoY), while the FY2025 annual figure was $1.7 million, up 2.21% from the prior year.
- Current Assets improved to $2.2 million in Q1 2026 per ESLA's latest filing, from $1.7 million in the prior quarter.
- Across five years, Current Assets topped out at $9.4 million in Q4 2023 and bottomed at $52427.0 in Q4 2022.
- Historically, Current Assets has averaged $2.4 million across 5 years, with a median of $1.7 million in 2024.
- Annual changes were most pronounced in 2022 — Current Assets plunged 91.49% — and 2023, when it surged 17919.84%.
- Estrella Immunopharma's Current Assets stood at $52427.0 in 2022, then soared by 17919.84% to $9.4 million in 2023, then slumped by 82.63% to $1.6 million in 2024, then gained by 2.21% to $1.7 million in 2025, then climbed by 28.64% to $2.2 million in 2026.
- Business Quant data shows ESLA's Current Assets at $2.2 million in Q1 2026, $1.7 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Estrella Immunopharma | 32.24 Mn | 32.10 Mn | - | 1.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.82 Mn |
| Mar 31, 2026 | 2.16 Mn |
| Dec 31, 2025 | 1.68 Mn |
| Sep 30, 2025 | 2.02 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 944,268.00 |
| Dec 31, 2024 | 1.64 Mn |
| Sep 30, 2024 | 2.24 Mn |
| Jun 30, 2024 | 4.45 Mn |
| Mar 31, 2024 | 8.63 Mn |
| Dec 31, 2023 | 9.45 Mn |
| Jun 30, 2023 | 2.75 Mn |
| Mar 31, 2023 | 81,890.00 |
| Dec 31, 2022 | 52,427.00 |
| Sep 30, 2022 | 160,752.00 |
| Jun 30, 2022 | 128,822.00 |
| Mar 31, 2022 | 428,140.00 |
| Dec 31, 2021 | 616,034.00 |
| Sep 30, 2021 | 780,134.00 |